Victory Capital Management
CCCC icon

Victory Capital Management’s C4 Therapeutics CCCC Stock Holding History

Victory Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16,409
Closed -$141K – 2707
2022
Q1 		$141K Sell
16,409
-121
-0.7% -$2.94K ﹤0.01% 2466
2021
Q4 		$532K Buy
16,530
+6,387
+63% +$253K ﹤0.01% 2116
2021
Q3 		$453K Buy
10,143
+838
+9% +$35.9K ﹤0.01% 2218
2021
Q2 		$352K Buy
9,305
+947
+11% +$33.9K ﹤0.01% 2360
2021
Q1 		$309K Buy
+8,358
New +$332K ﹤0.01% 2383

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management's CCCC Position: Q2 2022 in Review

Victory Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 16,409 shares — an estimated $141K sold.

Victory Capital Management first reported a position in CCCC in Q1 2021 and held it in 5 quarters. The position peaked at $532K in Q4 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • Victory Capital Management reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Victory Capital Management sold 16,409 C4 Therapeutics shares in Q2 2022, an estimated $141K.
  • Victory Capital Management first reported a position in C4 Therapeutics in Q1 2021 and held it in 5 quarters.
  • Victory Capital Management's C4 Therapeutics position peaked at $532K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on Victory Capital Management's 13F filing for Q2 2022, filed 1 Aug 2022.